BRPI0922090A2 - composição líquida ou líquida-congelada, método para estabilizar uma composição líquida ou líquida-congelada, e, uso de manitol - Google Patents

composição líquida ou líquida-congelada, método para estabilizar uma composição líquida ou líquida-congelada, e, uso de manitol

Info

Publication number
BRPI0922090A2
BRPI0922090A2 BRPI0922090A BRPI0922090A BRPI0922090A2 BR PI0922090 A2 BRPI0922090 A2 BR PI0922090A2 BR PI0922090 A BRPI0922090 A BR PI0922090A BR PI0922090 A BRPI0922090 A BR PI0922090A BR PI0922090 A2 BRPI0922090 A2 BR PI0922090A2
Authority
BR
Brazil
Prior art keywords
liquid
frozen composition
mannitol
stabilizing
frozen
Prior art date
Application number
BRPI0922090A
Other languages
English (en)
Inventor
Christa Tauer
Falkoguenter Falkner
Manfred Oberreither
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of BRPI0922090A2 publication Critical patent/BRPI0922090A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0922090A 2008-11-14 2009-11-13 composição líquida ou líquida-congelada, método para estabilizar uma composição líquida ou líquida-congelada, e, uso de manitol BRPI0922090A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/271,522 US7998488B2 (en) 2008-11-14 2008-11-14 Vaccine formulations and uses thereof
PCT/US2009/064382 WO2010056991A1 (en) 2008-11-14 2009-11-13 Vaccine formulations and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0922090A2 true BRPI0922090A2 (pt) 2015-12-15

Family

ID=41507986

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922090A BRPI0922090A2 (pt) 2008-11-14 2009-11-13 composição líquida ou líquida-congelada, método para estabilizar uma composição líquida ou líquida-congelada, e, uso de manitol

Country Status (9)

Country Link
US (2) US7998488B2 (pt)
EP (1) EP2358387B1 (pt)
JP (1) JP5642080B2 (pt)
KR (1) KR20110092307A (pt)
CN (1) CN102215866A (pt)
AU (1) AU2009313912B2 (pt)
BR (1) BRPI0922090A2 (pt)
CA (1) CA2747918C (pt)
WO (1) WO2010056991A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998488B2 (en) * 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
TWI527598B (zh) * 2009-05-18 2016-04-01 英特威特國際股份有限公司 將致免疫組成物維持可供投與動物的方法
AU2012212463B2 (en) 2011-01-31 2016-07-07 Nanotherapeutics, Inc. Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
US8420617B2 (en) 2011-03-11 2013-04-16 Biocell Laboratories Multiantivirus compound, composition and method for treatment of virus diseases
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
DK3226894T3 (da) * 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
CN109072582B (zh) 2016-04-19 2022-02-08 沃尔沃建筑设备公司 用于材料的倾倒的控制单元
JP7051132B2 (ja) 2016-09-16 2022-04-11 ロイコケア・アクチェンゲゼルシャフト ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
BR112022017438A2 (pt) 2020-03-12 2022-10-18 Bavarian Nordic As Composições que melhoram a estabilidade do poxvírus

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2879202A (en) * 1954-11-05 1959-03-24 American Cyanamid Co Stabilization of live viral vaccines by hexahydric alcohols
US3577524A (en) * 1968-03-04 1971-05-04 American Cyanamid Co Dimethylpolysiloxane suspensions of biologics and preparation thereof
FR7773M (pt) 1968-06-14 1970-03-23
US4147772A (en) 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
US4824668A (en) 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
WO1991009940A1 (en) * 1989-12-29 1991-07-11 Symex Corp. Stable formulation of viral neuraminidase
AT393277B (de) 1990-01-04 1991-09-25 Immuno Ag Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
CA2799545A1 (en) 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
US20030215455A1 (en) 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
EP1575611A4 (en) 2002-12-23 2007-10-03 Hope City MODIFIED P53-EXPRESSING VACCINIAANKARA IN CANCER IMMUNOTHERAPY
US6960345B2 (en) 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
EP1692279A4 (en) 2003-11-19 2006-12-27 Merck & Co Inc VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
CN1321694C (zh) 2005-05-20 2007-06-20 吉林大学 冻干剂型艾滋病重组痘病毒安卡拉株载体疫苗及其制备方法
AU2007317847B2 (en) * 2006-11-07 2013-10-31 Sanofi Pasteur Biologics, Llc Stabilization of vaccines by lyophilization
PT2144998T (pt) * 2007-04-06 2017-04-07 Takeda Vaccines Inc Métodos e composições para vírus vivos atenuados
US7998488B2 (en) * 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof

Also Published As

Publication number Publication date
WO2010056991A1 (en) 2010-05-20
EP2358387A1 (en) 2011-08-24
JP5642080B2 (ja) 2014-12-17
KR20110092307A (ko) 2011-08-17
CA2747918A1 (en) 2010-05-20
JP2012508766A (ja) 2012-04-12
AU2009313912A1 (en) 2010-05-20
CN102215866A (zh) 2011-10-12
WO2010056991A8 (en) 2010-07-08
EP2358387B1 (en) 2017-04-19
CA2747918C (en) 2018-10-02
AU2009313912B2 (en) 2015-04-16
US20120201847A1 (en) 2012-08-09
US8795683B2 (en) 2014-08-05
US20100124557A1 (en) 2010-05-20
US7998488B2 (en) 2011-08-16

Similar Documents

Publication Publication Date Title
BRPI0922090A2 (pt) composição líquida ou líquida-congelada, método para estabilizar uma composição líquida ou líquida-congelada, e, uso de manitol
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0913739A2 (pt) Composição líquida, método, e, uso de composição
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0907663A8 (pt) composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições
BR112012028719A2 (pt) composição de tratamento de superfície dura, método para fornecer um efeito antimicrobiano a uma superfície dura e uso de uma combinação
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0920272A2 (pt) composição de filtro-solar, método para melhorar a resistência à água de uma composição de filtro-solar, método para melhorar a eficácia de filtro-solar, e, formulação de filtro-solar
BRPI0916884A2 (pt) composição imunogênica, processo para preparar uma composição imunogênica, uso de uma composição imunogênica, e, kit
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0923513A2 (pt) método e composições para uso de uma vacina de coccidiose
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0921546A2 (pt) Compostos de arilazol-2-il cianoetilamina enriquecidos enantiomericamente, método para fabricação e método de uso dos mesmos
BRPI1014316A2 (pt) composição, e, uso de uma composição
BRPI0921399A2 (pt) composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante
BRPI0918487A2 (pt) processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero
BRPI0910963A2 (pt) composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica
BRPI0916575A2 (pt) composição de graxa lubrificante, e, uso de uma composição de graxa lubrificante
BR112014013614A8 (pt) composição antimicrobiana, método para desinfetar uma superfície e uso de uma composição
BR112012004173A2 (pt) "composto, composição, método para preparar uma composição, e, uso de um composto"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]